WEDNESDAY, April 24, 2024 (HealthDay News) — A budget-busting 3.6 million Medicare recipients could now be eligible for coverage of the weight-loss drug Wegovy, a new KFF analysis says. That’s because the U.S. Food and Drug Administration has approved the use of Wegovy (semaglutide) to reduce the risk of heartContinue Reading

FRIDAY, March 22, 2024 (HealthDay News) — Medicare will now cover the popular weight-loss drug Wegovy if patients using it also have heart disease, U.S. officials announced Thursday. The move comes after the U.S. Food and Drug Administration approved drugmaker Novo Nordisk’s application to add cardiovascular benefits to the medicine’s label earlierContinue Reading